logo
Twitter
Discord
Email
logo
Surmodics, Inc.

Surmodics, Inc.

NASDAQ•SRDX
CEO: Mr. Gary R. Maharaj
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1998-03-04
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Contact Information
9924 West 74th Street, Eden Prairie, MN, 55344-3523, United States
952-500-7000
www.surmodics.com
Market Cap
$392.25M
P/E (TTM)
-22.2
vs Industry 44.7
Dividend Yield (TTM)
--
52W High
$40.39
52W Low
$26.00
52W Range
10%
3.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$29.57M-2.55%
4-Quarter Trend

EPS

-$0.37-30.19%
4-Quarter Trend

FCF

$904.00K-130.21%
4-Quarter Trend

Earnings Highlights

Key Highlights

No Data Available

Risk Factors

No Data Available

Outlook

No Data Available

Peer Comparison

Revenue (TTM)

Varex Imaging CorporationVREX
$821.40M
-1.4%
OrthoPediatrics Corp.KIDS
$227.41M
+26.1%
OrthoPediatrics Corp.KIDS
$227.41M
+19.9%

Gross Margin (Latest Quarter)

Semler Scientific, Inc.SMLR
91.0%
-0.3 pp
Delcath Systems, Inc.DCTH
86.3%
+5.8 pp
Treace Medical Concepts, Inc.TMCI
79.7%
-0.6 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
VREX$485.15M-3.7-25.5%2.3%
BNTC$429.46M-15.6-45.3%0.9%
KIDS$422.30M-8.6-13.0%9.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
-3.8%
Flat Growth
4-Quarter Net Income CAGR
N/M
Profitability Shift Observed
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Jun 30, 2025|Filed: Aug 8, 2025|
    Revenue: $29.57M-2.6%
    |
    EPS: $-0.37-30.2%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Mar 31, 2025|Filed: Apr 30, 2025|
    Revenue: $28.09M-12.1%
    |
    EPS: $-0.36-2157.1%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Dec 31, 2024|Filed: Jan 30, 2025|
    Revenue: $29.92M-2.1%
    |
    EPS: $-0.26+366.8%
    Miss
  • Form 10-K - FY 2024

    Period End: Sep 30, 2024|Filed: Nov 20, 2024|
    Revenue: $126.08M-4.9%
    |
    EPS: $-0.82-645.5%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Jun 30, 2024|Filed: Jul 31, 2024|
    Revenue: $30.34M-42.2%
    |
    EPS: $-0.53-201.9%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Mar 31, 2024|Filed: May 1, 2024|
    Revenue: $31.96M+17.5%
    |
    EPS: $0.02-103.2%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Dec 31, 2023|Filed: Feb 1, 2024|
    Revenue: $30.55M+22.5%
    |
    EPS: $-0.06-90.1%
    Beat
  • Form 10-K - FY 2023

    Period End: Sep 30, 2023|Filed: Nov 22, 2023|
    Revenue: $132.58M+32.6%
    |
    EPS: $-0.11+94.4%
    Miss